Next date
None yet
Trials
0 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Ensitrelvir will be administered per schedule specified in the arm description.”In the company’s words, NCT06775730 on ClinicalTrials.gov
- Tested for
- SARS-CoV-2 Infection (2 trials), Renal Impairment, Hepatic Impairment
- Main trialPhase 3
- “The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.”In the company’s words, NCT05305547 on ClinicalTrials.gov
- Other names
- S-217622 · XOCOVA
Other drugs for SARS-CoV-2 Infection
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 7 Jan 2024 | A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 | |
| Phase 3Completed | 30 Aug 2024 | Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection | |
| Phase 1Completed | 12 Apr 2023 | A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants | |
| Phase 1Completed | 25 Apr 2023 | A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants | |
| Phase 1Completed | 3 Apr 2025 | A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026